Bausch + Lomb to initiate clinical trials for Technolas Teneo excimer laser

Bausch + Lomb will begin a clinical trial series of its Technolas Teneo excimer laser for vision correction surgery, the company announced in a press release.

Designed to correct myopia and myopic astigmatism, the Technolas Teneo laser system is the same as the model currently sold outside of the United States, the release said.

“The global LASIK market continues to grow, and the Technolas Teneo laser, which has a compact footprint, has been well received and widely adopted in more than 50 countries,” Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb, said in the release. “Our plan to initiate a series of clinical trials, and ultimately pursue regulatory approval for this technology in the United States, is part of our commitment providing surgeons with a full suite of innovations to meet the needs of their patients.”

The company plans to file for premarket approval of the laser with the FDA at the conclusion of the clinical trials.

Bausch + Lomb will begin a clinical trial series of its Technolas Teneo excimer laser for vision correction surgery, the company announced in a press release.

Designed to correct myopia and myopic astigmatism, the Technolas Teneo laser system is the same as the model currently sold outside of the United States, the release said.

“The global LASIK market continues to grow, and the Technolas Teneo laser, which has a compact footprint, has been well received and widely adopted in more than 50 countries,” Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb, said in the release. “Our plan to initiate a series of clinical trials, and ultimately pursue regulatory approval for this technology in the United States, is part of our commitment providing surgeons with a full suite of innovations to meet the needs of their patients.”

The company plans to file for premarket approval of the laser with the FDA at the conclusion of the clinical trials.